

10/523722

T05 Rec'd PCT/PTO 07 FEB 2005  
Sheet 1 of 1

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 026220-00062	SERIAL NO. 10/523,722 New Application
LIST OF REFERENCES CITED BY APPLICANT  (Use several sheets if necessary)		APPLICANT Piero DEL SOLDATO, et al.	
		FILING DATE February 7, 2005	GROUP Unknown

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO PART.		
FTP	AG	WO 95 09831 A	4/13/1995	WIPO Japan	—	—			
FTP	AH	WO 98 25918 A	6/18/1998	WIPO Japan	—	—			
FTP	AI	WO 01 10814 A	2/15/2001	WIPO Japan	—	—			

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

FTP	AM	KAWASHIMA, et al.; "Synthesis and Pharmacological Evaluation of (Nitrooxy)alkyl Appovincaminates"; Vol.36; Pgs. 815-819; 1993
	AN	OGAWA, et al.; "Synthesis and Antihypertensive Activities of New 1,4-Dihydropyridine Derivatives Containing Nitrooxyalkylester Moieties at the 3-And 5-Positions"; Vol.41, No.6, June 1993
	AO	Derwent Publications Ltd.; Kawaken Fine Chem. Co. Ltd.; JP 05 279359 A; October 26, 1993
	AP	ABADI, et al.; "Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl) propanoic acid (naproxen) derivatives"; Vol.334, No.3, Pgs. 104-106; 2001
FTP	AQ	GIORDANO, et al. "A Stereoconvergent Strategy for the Synthesis of Enantiomerically Pure (R)-(-) and (S)-(+)-2-(6-Methoxy-2-Naphthyl)-Propanoic Acid (Naproxen)"; Vol. 45, No. 13; Pgs. 4243-52; 1989

EXAMINER /Fiona T. Powers/	DATE CONSIDERED 01/03/2007
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB Indicates that only an English language abstract is attached.

5/5/05

PTO/SB/08b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Form PTO/SB/08b				Application Number	10/523,722 (Unofficial)
				Filing Date	February 7, 2005
				First Named Inventor	Piero DEL SOLDATO, et al.
				Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	1	Attorney Docket Number	026220-00062

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
FTP		Yutaka KAWASHIMA, et al.; "Synthesis and Pharmacological Evaluation of (Nitrooxy) alkyl Apovincaminates"; J. Med. Chem, 1993, Volume 36, No. 7, Pages 815-819	XX
		Toshihisa OGAWA, et al.; "Synthesis and Antihypertensive Activities of New 1,4-Dihydropyridine Derivatives Containing Nitrooxyalkylester Moieties at the 3- and 5-Positions"; Chem. Pharm. Bull. 1993, Vol. 41, No. 6, Pages 1049-1054	XX
		Claudio GIORDANO, et al.; "A Stereoconvergent Strategy For the Synthesis of Enantiomerically Pure (R)-(-) and (S)-(+)-2-(6-Methoxy-2-Naphthyl)-Propanoic Acid (Naproxen); 1989, Vol. 45, No. 13, Pages 4243-4252	XX
		Ashraf H. ABADI, et al.; "Synthesis and Cyclooxygenase Inhibitory Properties of Novel (+) 2-(6-Methoxy-2-naphthyl)propanoic Acid (Naproxene) Derivatives" 2001, Pages 104-106	XX
FTP		Kawaken Fine Chem. Co., Ltd.; "Derwent Publications Ltd.; Section Ch, Week 199347, 10/26/1993	XX

Examiner Signature	/Fiona T. Powers/	Date Considered	01/03/2007
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.